Rheumatology is branch of medicine that deals with the diagnosis and treatment of disorders of connective tissues and joints, many of which are now known to be immune mediated conditions.
Rheumatic diseases can be caused by trauma, heredity, genetic abnormality, autoimmune disease, or another underlying condition such as cancer. There are more than 150 different types of rheumatic disorders, including arthritis, rheumatoid and osteoarthritis, gout and lupus.
Featured Learning Zones
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Related news and insights
Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has approved Tremfya (guselkumab injection) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.
AbbVie announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for Rinvoq (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis.
Gilead Sciences, Inc. has announced that the FDA has issued a complete response letter (CRL) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA).